Company profile
Erasca, Inc.
NASDAQ:ERASBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Cetuximab | phase1_2 | — | 47 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04670679 | phase1 | active_not_recruiting | 2020-12-15 | 2026-02-01 | Erasca, Inc. | A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors |
| NCT04959981 | phase1 | completed | 2021-09-02 | 2023-04-27 | Erasca, Inc. | A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC |
| NCT05279859 | phase1_2 | withdrawn | 2022-03-15 | 2025-03-01 | Erasca, Inc. | A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies |
| NCT06983743 | phase1 | recruiting | 2025-06-05 | 2028-05-01 | Erasca, Inc. | A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors |
| NCT04866134 | phase1_2 | active_not_recruiting | 2021-05-07 | 2026-11-01 | Erasca, Inc. | A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors |
FDA applications (0)
No records yet.